Bush Proposes $2.8 Billion Increase For NIH In FY2002, Vows $4.1B Next Year.
ACOR Opens Cancer-pain.org
Connie Mack Joins Washington Office Of Shaw Pittman.
Richard Wood, ICRF, Accepts Appointment At Pittsburgh.
Cancer Groups In Campaign To Draft Pazdur For FDA.
NCI Seeks 150 Advocates For Advice On Plans, Policies.
“Harm-Reduction” Products No Proven, IOM Report Says.
MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.
FDA Approves Two PSA Tests By roche; Onconase Gets EU Orphan Designation.
Ilex Oncology Buys Symphar, Controls Drug For Bone Mets.
Response Oncology Sells Practice Back To Physicians.
EntreMed Issued U.S. Patent For Active Parts Of Endostatin.
Trending Stories
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research
- The White House “skinny budget” document cuts NIH by nearly 40%
The cuts are consistent with the previously leaked “passback” document - NIH cuts threaten U.S. edge in biomedical research: “We are giving China the opportunity of a lifetime”
Cancer research also took center stage at Senate appropriations hearing - In The Headlines: Are cancer registries on the chopping block, and what does it mean if they are?
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated
